link to appointment info link to faculty and staff info link to research info related links

UAB Neurology Clinic for
Rett Syndrome

Welcome to the UAB Civitan-Sparks Clinics Neurology Clinic and Rett Syndrome Research web site. Here you will find detailed information about Rett Syndrome along with links to research, clinic appointments, and international online resources related to Rett Syndrome.

The UAB Neurology Clinic for Rett Syndrome in the UAB Civitan-Sparks Clinics, a component of the Civitan International Research Center (CIRC) has been operational since 1992. The clinic provides comprehensive evaluations for children with or suspected of having Rett Syndrome.

The clinic and its research activities are directed by Alan Percy, M.D., Associate Director of the CIRC. Dr. Percy is an internationally recognized expert in the diagnosis and care of children with Rett Syndrome. The clinic has access to a full range of health professionals available within the Civitan-Sparks Clinics and The Children’s Hospital of Alabama.

Appointments: Clinic appointments are typically made through referring physicians but inquiries and appointments can be made by calling Jan Reeves at 205-934-1055 or toll-free at 1-800-822-2472.

About Rett Syndrome

Rett Syndrome (RS) is a neurological disorder seen almost exclusively in females. The prevalence of RS in females is approximately one in every 10,000-23,000 individuals and is found in all racial and ethnic groups worldwide. It is known that RS can occur in males but is extremely rare. Recurrence in families is also extremely rare. In these families males may have a very different pattern including miscarriage, stillbirth or early death due to fatal encephalopathy.

RS has its clinical onset in most females between 6-18 months of age. Development to that time appears normal. This is followed by a period of stagnation or regression during which the child begins losing communication skills and purposeful use of the hands. Afterwards, stereotypical hand movements (such as hand wringing or knitting motions), gait disturbances, and a slowed rate of head growth may be observed.

In 1999 a decade-long search for the genetic basis for RS succeeded in identifying mutations in the MECP2 gene in girls fulfilling the criteria for RS. This discovery allows confirmation of clinical diagnoses and the development of genotype-phenotype correlations. We are now examining the molecular genetics of children who do not meet all diagnostic criteria for RS, but who are near the border zones of clinical involvement. At the present time, more than 80% of females fulfilling the criteria for RS have mutations in MECP2. The remainder either has mutations in as yet unexplored regions of MECP2 or is explained by alternative genes.

Predicting the severity of RS for an individual is difficult because more than 200 mutations in the MECP2 gene have been observed. The range of these mutations result in varying degrees of neurological and physical complications and may also lead to misdiagnosis by health professionals who may not be familiar with RS. It is most often misdiagnosed as autism, cerebral palsy or other forms of developmental delay. Correct diagnosis is essential to receiving quality treatment. It is strongly suggested to parents that a diagnosis should be obtained through a clinical evaluation using agreed upon clinical criteria and clinical severity scales.

Most researchers now agree that RS is a developmental disorder rather than a progressive, degenerative disorder as once thought. Survival into adulthood is now expected barring other illnesses or serious physical complications. Girls and women with RS can be expected to demonstrate a full range of emotions and enjoy satisfying social, recreational, and educational experiences at home and in the community.


Back to top of page